Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder Symptoms
Multiple randomized controlled trials (RCTs) have examined first-line pharmacological agents such as anticholinergics and β3 agonists for the management of overactive bladder symptoms (OAB). Although earlier systematic reviews and (network) meta-analyses aimed to summarize the evidence, a substantia...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-11-01
|
| Series: | European Urology Open Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266616832400630X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850206365081927680 |
|---|---|
| author | Henk van der Worp Angie K. Puerto Nino Marco H. Blanker Romina Brignardello-Petersen Gordon H. Guyatt Kari A.O. Tikkinen Arnav Agarwal Yoshitaka Aoki Scott R. Bauer Neera Bhatnagar Kostiantyn Bolsunovskyi Gerhard H. te Brummelstroete Jovita L. Cárdenas Rufus Cartwright Dean Elterman Leyla Eryuzlu Pramila Gaudel Rachel E. Gutschon Tomas L. Griebling Sanna K. Hallamies Katriina Heikkilä Zain Izhar Tuomas P. Kilpeläinen Saqib Khurshid Sanna M. Laakkonen Yung Lee Luciane C. Lopes Anne Loohuis Alexander Mendieta Henri Mynttinen Hanieh Salehi-Pourmehr Alexey Pryalukhin Mikolaj Przydacz Fahad J. Siddiqui Riikka Tähtinen Robin W.M. Vernooij Philippe D. Violette Lambertus P.W. Witte Koji Yoshimura |
| author_facet | Henk van der Worp Angie K. Puerto Nino Marco H. Blanker Romina Brignardello-Petersen Gordon H. Guyatt Kari A.O. Tikkinen Arnav Agarwal Yoshitaka Aoki Scott R. Bauer Neera Bhatnagar Kostiantyn Bolsunovskyi Gerhard H. te Brummelstroete Jovita L. Cárdenas Rufus Cartwright Dean Elterman Leyla Eryuzlu Pramila Gaudel Rachel E. Gutschon Tomas L. Griebling Sanna K. Hallamies Katriina Heikkilä Zain Izhar Tuomas P. Kilpeläinen Saqib Khurshid Sanna M. Laakkonen Yung Lee Luciane C. Lopes Anne Loohuis Alexander Mendieta Henri Mynttinen Hanieh Salehi-Pourmehr Alexey Pryalukhin Mikolaj Przydacz Fahad J. Siddiqui Riikka Tähtinen Robin W.M. Vernooij Philippe D. Violette Lambertus P.W. Witte Koji Yoshimura |
| author_sort | Henk van der Worp |
| collection | DOAJ |
| description | Multiple randomized controlled trials (RCTs) have examined first-line pharmacological agents such as anticholinergics and β3 agonists for the management of overactive bladder symptoms (OAB). Although earlier systematic reviews and (network) meta-analyses aimed to summarize the evidence, a substantial number of trials were not included, so a comprehensive and methodologically rigorous evaluation of the comparative effectiveness of all first-line pharmacological treatments is lacking. We aim to conduct a series of systematic reviews and network meta-analyses (NMAs) for a comprehensive assessment of the effectiveness and safety of first-line pharmacological treatments for OAB. Eligible studies will include RCTs comparing anticholinergics and β3 agonists to one another or to placebo in adults with OAB or detrusor overactivity. Pairs of reviewers with methodological training will independently evaluate candidate studies to determine eligibility and extract relevant data. We will incorporate patient-important outcomes, including urinary urgency episodes, urgency incontinence episodes, any type of incontinence episodes, urinary frequency, nocturia, and adverse events. We will conduct the NMAs using a frequentist framework and a graph theory model for each outcome. Analysis will follow rigorous methodologies, including handling of missing data and assessment of the risk of bias. We will conduct sensitivity and subgroup analyses and will apply the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to rate evidence certainty. Our approach aims to address the knowledge gap in the treatment of OAB by synthesizing evidence from RCTs worldwide. We will employ robust statistical methods, including frequentist NMA, to general clinically relevant and patient-important insights. Sensitivity and subgroup analyses will enhance the robustness and generalizability of our findings. Our reviews strive to inform evidence-based decisions in the management of OAB, to ultimate improve patient outcomes. Our study results may guide health policy decisions, such as reimbursement policies, and future studies in functional urology.The protocol for the review series is registered on PROSPERO as CRD42023266915. |
| format | Article |
| id | doaj-art-c7c782b89a7f44da8006b3e5c32bcfe3 |
| institution | OA Journals |
| issn | 2666-1683 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Elsevier |
| record_format | Article |
| series | European Urology Open Science |
| spelling | doaj-art-c7c782b89a7f44da8006b3e5c32bcfe32025-08-20T02:10:50ZengElsevierEuropean Urology Open Science2666-16832024-11-0169899910.1016/j.euros.2024.08.006Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder SymptomsHenk van der Worp0Angie K. Puerto Nino1Marco H. Blanker2Romina Brignardello-Petersen3Gordon H. Guyatt4Kari A.O. Tikkinen5Arnav AgarwalYoshitaka AokiScott R. BauerNeera BhatnagarKostiantyn BolsunovskyiGerhard H. te BrummelstroeteJovita L. CárdenasRufus CartwrightDean EltermanLeyla EryuzluPramila GaudelRachel E. GutschonTomas L. GrieblingSanna K. HallamiesKatriina HeikkiläZain IzharTuomas P. KilpeläinenSaqib KhurshidSanna M. LaakkonenYung LeeLuciane C. LopesAnne LoohuisAlexander MendietaHenri MynttinenHanieh Salehi-PourmehrAlexey PryalukhinMikolaj PrzydaczFahad J. SiddiquiRiikka TähtinenRobin W.M. VernooijPhilippe D. VioletteLambertus P.W. WitteKoji YoshimuraDepartment of Primary and Long-term Care, University of Groningen, University Medical Center Groningen, Groningen, The NetherlandsFaculty of Medicine, University of Helsinki, Helsinki, Finland; Division of Urology, Department of Surgery, University of Toronto, Toronto, Canada; Corresponding authors. Faculty of Medicine, University of Helsinki, Biomedicum 2B, P.O. Box 13, Tukholmankatu 8 B, 00290 Helsinki, Finland.Department of Primary and Long-term Care, University of Groningen, University Medical Center Groningen, Groningen, The NetherlandsDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, CanadaDepartment of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada; Department of Medicine, McMaster University, Hamilton, CanadaFaculty of Medicine, University of Helsinki, Helsinki, Finland; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Canada; Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Surgery, South Karelian Central Hospital, Lappeenranta, Finland; Corresponding authors. Faculty of Medicine, University of Helsinki, Biomedicum 2B, P.O. Box 13, Tukholmankatu 8 B, 00290 Helsinki, Finland.Multiple randomized controlled trials (RCTs) have examined first-line pharmacological agents such as anticholinergics and β3 agonists for the management of overactive bladder symptoms (OAB). Although earlier systematic reviews and (network) meta-analyses aimed to summarize the evidence, a substantial number of trials were not included, so a comprehensive and methodologically rigorous evaluation of the comparative effectiveness of all first-line pharmacological treatments is lacking. We aim to conduct a series of systematic reviews and network meta-analyses (NMAs) for a comprehensive assessment of the effectiveness and safety of first-line pharmacological treatments for OAB. Eligible studies will include RCTs comparing anticholinergics and β3 agonists to one another or to placebo in adults with OAB or detrusor overactivity. Pairs of reviewers with methodological training will independently evaluate candidate studies to determine eligibility and extract relevant data. We will incorporate patient-important outcomes, including urinary urgency episodes, urgency incontinence episodes, any type of incontinence episodes, urinary frequency, nocturia, and adverse events. We will conduct the NMAs using a frequentist framework and a graph theory model for each outcome. Analysis will follow rigorous methodologies, including handling of missing data and assessment of the risk of bias. We will conduct sensitivity and subgroup analyses and will apply the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to rate evidence certainty. Our approach aims to address the knowledge gap in the treatment of OAB by synthesizing evidence from RCTs worldwide. We will employ robust statistical methods, including frequentist NMA, to general clinically relevant and patient-important insights. Sensitivity and subgroup analyses will enhance the robustness and generalizability of our findings. Our reviews strive to inform evidence-based decisions in the management of OAB, to ultimate improve patient outcomes. Our study results may guide health policy decisions, such as reimbursement policies, and future studies in functional urology.The protocol for the review series is registered on PROSPERO as CRD42023266915.http://www.sciencedirect.com/science/article/pii/S266616832400630XOveractive bladderNetwork meta-analysisMultiple comparisonsTreatmentClinical outcomesRisk of bias |
| spellingShingle | Henk van der Worp Angie K. Puerto Nino Marco H. Blanker Romina Brignardello-Petersen Gordon H. Guyatt Kari A.O. Tikkinen Arnav Agarwal Yoshitaka Aoki Scott R. Bauer Neera Bhatnagar Kostiantyn Bolsunovskyi Gerhard H. te Brummelstroete Jovita L. Cárdenas Rufus Cartwright Dean Elterman Leyla Eryuzlu Pramila Gaudel Rachel E. Gutschon Tomas L. Griebling Sanna K. Hallamies Katriina Heikkilä Zain Izhar Tuomas P. Kilpeläinen Saqib Khurshid Sanna M. Laakkonen Yung Lee Luciane C. Lopes Anne Loohuis Alexander Mendieta Henri Mynttinen Hanieh Salehi-Pourmehr Alexey Pryalukhin Mikolaj Przydacz Fahad J. Siddiqui Riikka Tähtinen Robin W.M. Vernooij Philippe D. Violette Lambertus P.W. Witte Koji Yoshimura Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder Symptoms European Urology Open Science Overactive bladder Network meta-analysis Multiple comparisons Treatment Clinical outcomes Risk of bias |
| title | Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder Symptoms |
| title_full | Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder Symptoms |
| title_fullStr | Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder Symptoms |
| title_full_unstemmed | Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder Symptoms |
| title_short | Protocol for a Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials of Medications for Patients with Overactive Bladder Symptoms |
| title_sort | protocol for a series of systematic reviews and network meta analyses of randomized controlled trials of medications for patients with overactive bladder symptoms |
| topic | Overactive bladder Network meta-analysis Multiple comparisons Treatment Clinical outcomes Risk of bias |
| url | http://www.sciencedirect.com/science/article/pii/S266616832400630X |
| work_keys_str_mv | AT henkvanderworp protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT angiekpuertonino protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT marcohblanker protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT rominabrignardellopetersen protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT gordonhguyatt protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT kariaotikkinen protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT arnavagarwal protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT yoshitakaaoki protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT scottrbauer protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT neerabhatnagar protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT kostiantynbolsunovskyi protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT gerhardhtebrummelstroete protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT jovitalcardenas protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT rufuscartwright protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT deanelterman protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT leylaeryuzlu protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT pramilagaudel protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT rachelegutschon protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT tomaslgriebling protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT sannakhallamies protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT katriinaheikkila protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT zainizhar protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT tuomaspkilpelainen protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT saqibkhurshid protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT sannamlaakkonen protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT yunglee protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT lucianeclopes protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT anneloohuis protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT alexandermendieta protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT henrimynttinen protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT haniehsalehipourmehr protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT alexeypryalukhin protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT mikolajprzydacz protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT fahadjsiddiqui protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT riikkatahtinen protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT robinwmvernooij protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT philippedviolette protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT lambertuspwwitte protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms AT kojiyoshimura protocolforaseriesofsystematicreviewsandnetworkmetaanalysesofrandomizedcontrolledtrialsofmedicationsforpatientswithoveractivebladdersymptoms |